The hardware and bandwidth for this mirror is donated by dogado GmbH, the Webhosting and Full Service-Cloud Provider. Check out our Wordpress Tutorial.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]dogado.de.

CePa: Centrality-Based Pathway Enrichment

It aims to find significant pathways through network topology information. It has several advantages compared with current pathway enrichment tools. First, pathway node instead of single gene is taken as the basic unit when analysing networks to meet the fact that genes must be constructed into complexes to hold normal functions. Second, multiple network centrality measures are applied simultaneously to measure importance of nodes from different aspects to make a full view on the biological system. CePa extends standard pathway enrichment methods, which include both over-representation analysis procedure and gene-set analysis procedure. <doi:10.1093/bioinformatics/btt008>.

Version: 0.8.0
Depends: R (≥ 3.6.0)
Imports: igraph (≥ 0.6), stats, graphics, methods, grDevices, parallel, Rgraphviz, graph
Published: 2022-06-11
Author: Zuguang Gu ORCID iD [aut, cre]
Maintainer: Zuguang Gu <z.gu at dkfz.de>
License: GPL-2 | GPL-3 [expanded from: GPL (≥ 2)]
URL: https://github.com/jokergoo/CePa
NeedsCompilation: no
In views: Omics
CRAN checks: CePa results

Documentation:

Reference manual: CePa.pdf
Vignettes: CePa Vignette
analysis-p53
parsing-PID

Downloads:

Package source: CePa_0.8.0.tar.gz
Windows binaries: r-devel: CePa_0.8.0.zip, r-release: CePa_0.8.0.zip, r-oldrel: CePa_0.8.0.zip
macOS binaries: r-release (arm64): CePa_0.8.0.tgz, r-oldrel (arm64): CePa_0.8.0.tgz, r-release (x86_64): CePa_0.8.0.tgz, r-oldrel (x86_64): CePa_0.8.0.tgz
Old sources: CePa archive

Reverse dependencies:

Reverse suggests: RCPA

Linking:

Please use the canonical form https://CRAN.R-project.org/package=CePa to link to this page.

These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.
Health stats visible at Monitor.